Guy MacDonald
Président chez SCYNEXIS, INC.
Fortune : 32 340 $ au 30/04/2024
Profil
Guy MacDonald is currently the Chairman at SCYNEXIS, Inc. He previously served as Chairman at F-Star Therapeutics, Inc. and as Director at Tetraphase Pharmaceuticals, Inc. He also held the position of Vice President-Anti Infective & Hospital Products at Merck & Co., Inc. and Executive Vice President-Operations at Idenix Pharmaceuticals LLC.
Mr. MacDonald completed his undergraduate degree at the University Of Dundee.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SCYNEXIS, INC.
0,06% | 31/03/2024 | 22 000 ( 0,06% ) | 32 340 $ | 30/04/2024 |
Postes actifs de Guy MacDonald
| Sociétés | Poste | Début |
|---|---|---|
| SCYNEXIS, INC. | Président | 04/06/2015 |
Anciens postes connus de Guy MacDonald
| Sociétés | Poste | Fin |
|---|---|---|
| TETRAPHASE PHARMACEUTICALS, INC. | Directeur Général | 01/08/2019 |
| SPRING BANK PHARMACEUTICALS, INC. | Président | 17/08/2015 |
| IDENIX PHARMACEUTICALS INC | Directeur des opérations | 01/01/2008 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2003 |
Formation de Guy MacDonald
| University Of Dundee | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| SCYNEXIS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
F-Star Therapeutics, Inc. (United States)
 F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA. | Health Technology |
